Cargando…
Targeting Metabolic Symbiosis to Overcome Resistance to Anti-angiogenic Therapy
Despite the approval of several anti-angiogenic therapies, clinical results remain unsatisfactory, and transient benefits are followed by rapid tumor recurrence. Here, we demonstrate potent anti-angiogenic efficacy of the multi-kinase inhibitors nintedanib and sunitinib in a mouse model of breast ca...
Autores principales: | Pisarsky, Laura, Bill, Ruben, Fagiani, Ernesta, Dimeloe, Sarah, Goosen, Ryan William, Hagmann, Jörg, Hess, Christoph, Christofori, Gerhard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cell Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4870473/ https://www.ncbi.nlm.nih.gov/pubmed/27134168 http://dx.doi.org/10.1016/j.celrep.2016.04.028 |
Ejemplares similares
-
The FAK inhibitor BI 853520 exerts anti-tumor effects in breast cancer
por: Tiede, Stefanie, et al.
Publicado: (2018) -
Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling
por: Allen, Elizabeth, et al.
Publicado: (2016) -
Synergism of peptide receptor-targeted Auger electron radiation therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumors
por: Wicki, Andreas, et al.
Publicado: (2014) -
Mutational interactions define novel cancer subgroups
por: Kuipers, Jack, et al.
Publicado: (2018) -
Overcoming Intrinsic Doxorubicin Resistance in Melanoma by Anti-Angiogenic and Anti-Metastatic Effects of Liposomal Prednisolone Phosphate on Tumor Microenvironment
por: Licarete, Emilia, et al.
Publicado: (2020)